Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

A psychedelic renaissance

Fifty-three years after LSD was banned by the FDA, psychedelic drugs are making a comeback. Only instead of being the pills, mushrooms and acid tabs that helped college students to “turn on, tune in, drop out” Timothy Leary-style, today’...

Buzz on the Bullboards: The calm before another September rally?

It’s the last leg of what looks like an end-of-month rally as investors try to make the most of August’s losses. Traders are neck-deep into a data-heavy week from company fiscal reports that could chart the hike path for interest rates. ...

XPhyto: Innovating a Therapeutic Psychedelic Drug Pipeline

It’s been dubbed the Age of Anxiety. Yet it’s quickly becoming far worse than that. With the arrival of globalism, the new millennium has already become synonymous with the threat of deadly pandemics. And the onslaught of the worst of them s...

XPhyto: Is Mescaline the Next Big Mood-Modifying Medicine?

It has the potential to be the next frontier in the psychedelics renaissance, and it represents an unprecedented opportunity to innovate a notable advancement in mental health therapy. In anecdotal studies, mescaline has shown promise in treating depression, anxiety, PTSD,...

From a Failed Breakout to a Failed Breakdown

The historical action of the precious metals sector over the past few weeks has continued. The strong recovery in GDX, GDXJ, and Silver has potentially invalidated the technical breakdown that occurred during the crash. It appears to be a failed breakdown. Furthermor...

Will Gold Benefit from Trump Impeachment Proceedings?

This week, Nancy Pelosi announced that the House would launch a formal impeachment inquiry. Is it a well-grounded argument, publicity stunt or reflection of the growing polarization inside the Democratic party? Storm in a tea cup or not, should Trump be worried? And gold? W...

Marinus Pharma Shares Open Up 41% on Phase 2 Epilepsy Trial Results

Marinus Pharmaceuticals reported positive top-line results for ganaxolone in its Phase 2 refractory status epilepticus trial with all patients achieving the primary endpoint. This morning Marinus Pharmaceuticals Inc. (MRNS:NASDAQ) , a pharmaceutical firm dedicated to...

Tax loss selling…is it a good time for investors?

Every year on Black Friday, shoppers anticipate great deals and are lined out the door to get a discount on a TV or on a much needed appliance. Buyers will go to many lengths, including camping outside the store to be the first in or even trampling on other shoppers to get t...

Is Coronavirus the Black Swan That Takes Gold To-Da-Moon?

Amid the worries about the coronavirus and its impact on the global economy, the US yield curve has briefly inverted again. Recession, anyone? And what exactly does the inversion imply for the gold market? Yield Curve Inverts Again Ooops, it happened again – the yield ...

Increased Cannabis Interest Paves Way for Cannabinoid Production

As the cannabis market has started to recover amidst the COVID-19 pandemic, investors are looking at where the market can grow. One leading candidate is cannabinoid production. THC, CBD, and other specific cannabinoids can be useful for a variety of treatments, includ...
1 2 3 4 5 6 7 8 9 10 ...